Market Place
Sourcing Support
AmMax Bio doses first subjects in Phase IIb trial of TGCT therapy
30 Jan 2023 //
CLINICAL TRIALS ARENA
AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for TGCT
30 Jan 2023 //
GLOBENEWSWIRE
AmMax Bio`s AMB-05X Receives EMA PRIME Designation for the Treatment of TGCT
19 Jan 2023 //
GLOBENEWSWIRE
AmMax Enters into an Agreement with Evopoint to License ADC
09 Jan 2023 //
GLOBENEWSWIRE
AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X
18 Nov 2022 //
GLOBENEWSWIRE
AmMax Bio Provides Update on AMB-05X Program for (TGCT)
26 Sep 2022 //
GLOBENEWSWIRE
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X
12 Sep 2022 //
GLOBENEWSWIRE
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation
07 Sep 2022 //
GLOBENEWSWIRE
AmMax Bio Appoints Dorothy Nguyen, M.D. as VP of Clinical Development
25 Jul 2022 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.